The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly
Publication date
2015-12-15
Authors
Van Werkhoven, Cornelis H.
Huijts, Susanne M
Bolkenbaas, Marieke
Grobbee, Rick
Bonten, Marc
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
taverne
Abstract
In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.
Keywords
pneumococcal conjugate vaccine, community-acquired pneumonia, invasive pneumococcal disease, vaccine efficacy, immunosenescence, Taverne, Journal Article, Randomized Controlled Trial
Citation
van Werkhoven, C H, Huijts, S M, Bolkenbaas, M, Grobbee, D E & Bonten, M J M 2015, 'The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly', Clinical Infectious Diseases, vol. 61, no. 12, pp. 1835-1838. https://doi.org/10.1093/cid/civ686